Prelude Therapeutics
Michael Hulse has a wide range of experience in the field of research and science, having held positions at Prelude Therapeutics, The Wistar Institute, Temple University, and AstraZeneca. Michael's educational background includes a PhD from Temple University - Lewis Katz School of Medicine, an MSc in Biomedical Sciences from The University of Edinburgh, and a BSc in Pharmacology from the University of Liverpool.
Prelude Therapeutics
3 followers
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.